Showing results (1891-1900 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|October 7, 2009
Budget-impact analyses: a critical review of published studiesEwa Orlewska, Laszlo Gulácsi
Pharmacoeconomics|October 7, 2009
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare settingLaura McCullagh, Lesley Tilson, Cathal Walsh, et al.
Pharmacoeconomics|October 7, 2009
30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvementPeter J Neumann, Chi-Hui Fang, Joshua T Cohen
Pharmacoeconomics|July 31, 2009
Pharmacoeconomic considerations in treating actinic keratosisMarjorie V Neidecker, Mary Lynn Davis-Ajami, Rajesh Balkrishnan, et al.
Pharmacoeconomics|July 31, 2009
Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary diseaseMaureen P M H Rutten-van Mölken, Martine Hoogendoorn, Leida M Lamers
Pharmacoeconomics|July 31, 2009
Determinants of direct cost differences among US employees with major depressive disorders using antidepressantsHoward G Birnbaum, Rym Ben-Hamadi, Paul E Greenberg, et al.
Pharmacoeconomics|August 12, 2009
Societal and patient burden of fibromyalgia syndromeLieven Annemans, Katell Le Lay, Charles Taïeb
Pharmacoeconomics|May 15, 2020
Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple SclerosisNils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Pharmacoeconomics|May 15, 2020
Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility AnalysisJesse Elliott, Bláthnaid McCoy, Tammy Clifford, et al.
Pharmacoeconomics|August 30, 2021
A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United KingdomMaria Veronica Dorgali, Alberto Longo, Caroline Vass, et al.
Pageof 336